论文部分内容阅读
目的:探讨前列地尔和银杏达莫治疗糖尿病肾病的临床效果。方法:选取本院2014年收治的糖尿病肾病患者40例,入选患者随机分为A、B两组,A组患者给予前列地尔治疗,B组患者给予银杏达莫治疗。比较两组患者在治疗前血尿素氮(BUN)、肌酐(CRE)、血清胱抑素(CYS-C)、尿微量白蛋白/肌酐(U-MALB/GR)检验值的变化。结果:治疗前两组患者的BUN、CRE、CYS-C、U-MALB/GR检验值比较,差异无统计学意义(P>0.05);治疗结束后两组患者的BUN、CRE、CYS-C、U-MALB/GR检验值与治疗前比较均有变化(P<0.05);A组的CRE、CYS-C、U-MALB/GR检验值改变量明显优于B组(P<0.05);治疗后两组患者疗效评价,A组的有效率优于B组(P<0.05)。结论:前列地尔和银杏达莫对糖尿病肾病均有疗效,前列地尔的疗效略优于银杏达莫。
Objective: To investigate the clinical effects of alprostadil and gingko-damo in the treatment of diabetic nephropathy. Methods: 40 patients with diabetic nephropathy admitted to our hospital in 2014 were enrolled. All the patients were randomly divided into A and B groups. A group was treated with alprostadil while B group was treated with ginkgodam. The changes of BUN, CRE, CYS-C and U-MALB / GR before treatment were compared between the two groups. Results: There was no significant difference in the BUN, CRE, CYS-C and U-MALB / GR test scores between the two groups before treatment (P> 0.05) (P <0.05). The changes of CRE, CYS-C and U-MALB / GR in group A were significantly better than those in group B (P <0.05). The curative effect evaluation of two groups after treatment was better in group A than in group B (P <0.05). Conclusion: Alprostadil and ginkgodam have effects on diabetic nephropathy, and the effect of alprostadil is slightly better than that of ginkgo biloba.